Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMBRYZ7)

Drug Name

RG6292 Drug Info

Synonyms

CD25 mAb

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Interleukin 2 receptor alpha (IL2RA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Basiliximab	DMWNRZT	Organ transplant rejection	NE84	Approved	[3]
Inolimomab	DMUS1F8	Heart transplant rejection	NE84	Phase 3	[4]
RFT-5.dgA	DMQ8K93	Human immunodeficiency virus infection	1C62	Phase 2	[5]
LMB-2	DMG7RAV	Chronic lymphocytic leukaemia	2A82.0	Phase 2	[6]
CHT-25	DMJLZ8T	Hodgkin lymphoma	2B30	Phase 1	[7]
HuMax-TAC	DM8BSF3	Autoimmune diabetes	5A10	Terminated	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interleukin 2 receptor alpha (IL2RA)	TT10Y9E	IL2RA_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT04158583) A Study to Evaluate the Safety and Tolerability of RO7296682 in Participants With Advanced Solid Tumors.. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of Roche.
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4	Encouraging results with inolimomab (anti-IL-2 receptor) as treatment for refractory acute graft-versus-host disease.Biol Blood Marrow Transplant.2006 Nov;12(11):1135-41.
5	Clinical evaluation of ricin A-chain immunotoxins in patients with Hodgkin's lymphoma. Ann Oncol. 2003 May;14(5):729-36.
6	Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol. 2000 Apr;18(8):1622-36.
7	A Phase I Clinical Trial of CHT-25 a 131I-Labeled Chimeric Anti-CD25 Antibody Showing Efficacy in Patients with Refractory Lymphoma. Clin Cancer Res. 2009 Dec 15;15(24):7701-7710.
8	Biosynthesis, synthesis, and biological activities of pyrrolobenzodiazepines. Med Res Rev. 2012 Mar;32(2):254-93.